Adverse events related to treatment · non‐ambulatory children with SMA types II and III
Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Other primary menstrual bleeding and satisfaction outcomes: semi‐objectively assessed menstrual blood loss, subjectively assessed menstrual blood loss, participant satisfaction with treatment · heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).
1 finding from 1 review
Recurrent ischaemic or unknown stroke during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes recurrent ischaemic/unknown stroke during treatment period compared with control (very low certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Major extracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes major extracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Mean change in BMD of the femoral neck · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy
Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).
1 finding from 1 review
Breastfeeding · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Infant weight (where they were only receiving own mother's milk) at the end of the study (grams) ( · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Volume of breast milk at the latest time measured (mL) ( · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Adverse effects for the infant or mother · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Breastfeeding · increasing breast milk production in mothers of non‐hospitalised term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infant weight (where they were only receiving own mother's milk) at the end of the study (grams) ( · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Volume of breast milk at the latest time measured (mL) ‐ domperidone, metoclopramide, sulpiride ( · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Adverse effects for the infant or mother · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Change in disability score · children with SMA types II and III
1 finding from 1 review
Muscle strength · children with SMA types II and III
1 finding from 1 review
Acquiring the ability to stand or walk · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found